Department of Biological Sciences and Biotechnology, Tsinghua University, Beijing 10084, PR China.
Phytomedicine. 2011 Aug 15;18(11):985-9. doi: 10.1016/j.phymed.2011.03.002. Epub 2011 Jul 7.
Naringin is considered the main effective compound of Drynaria Rhizome, which is used commonly in the treatment of osteoporosis in traditional Chinese medicine. However, we found neoeriocitrin, a new compound isolated from Drynaria Rhizome, showed a better activity than naringin on proliferation and osteogenic differentiation in MC3T3-E1. Both neoeriocitrin and naringin exhibited the best effect on proliferation and osteogenic differentiation at concentration of 2μg/ml. Neoeriocitrin more significantly improved proliferation and alkaline phosphatase (ALP) activity as well as up-regulated Runx2, COLI and OCN expression by 56%, 37% and 14% respectively than naringin. Furthermore, neoeriocitrin could rescue the inhibition effect of cell differentiation induced by PD98059 to some degree. Therefore, neoeriocitrin may be a new promising candidate drug for treatment of osteoporosis.
柚皮苷被认为是中药密骨片中的主要有效化合物,常用于治疗骨质疏松症。然而,我们发现新橙皮苷,一种从密骨片中分离出的新化合物,在促进 MC3T3-E1 增殖和成骨分化方面的活性优于柚皮苷。新橙皮苷和柚皮苷在浓度为 2μg/ml 时对增殖和成骨分化的效果最佳。新橙皮苷能更显著地提高细胞增殖和碱性磷酸酶(ALP)活性,并分别上调 Runx2、COLI 和 OCN 的表达水平达 56%、37%和 14%,优于柚皮苷。此外,新橙皮苷在一定程度上能挽救 PD98059 诱导的细胞分化抑制作用。因此,新橙皮苷可能是一种治疗骨质疏松症的有前途的候选药物。